Premium
Synthesis of carbon‐14 labeled ketamine and norketamine
Author(s) -
Chen Lu,
Gong Yong,
Salter Rhys
Publication year - 2018
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.3669
Subject(s) - ketamine , chemistry , enantiomer , nmda receptor , metabolite , pharmacokinetics , pharmacology , stereochemistry , receptor , anesthesia , biochemistry , medicine
Ketamine is a well‐known general anesthetic that inhibits cerebral NMDA receptors. Norketamine is a major circulating metabolite of this drug. A nasal spray formulation of esketamine, the S enantiomer of ketamine, is under development for the management of treatment‐resistant depression. To assess the pharmacokinetic properties, C‐14 labeled ketamine and norketamine were prepared separately from commercially available [ 14 C]CuCN through a five‐step sequence with the C‐14 label at the quaternary carbon of the cyclohexyl ring. Chiral resolution of [ 14 C]ketamine and chiral column separation of [ 14 C]norketamine resolved/separated the ( S )‐enantiomers from ( R )‐enantiomers.